Baseline clinical characteristics of patients affected by rheumatoid and psoriatic refractory knee joint synovitis
| RA | PsA | |
|---|---|---|
| DMARD, disease modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; IA, intra-articular; KJS, knee joint synovitis; PsA, psoriatic arthritis; RA, rheumatoid arthritis; RF, rheumatoid factor. | ||
| Age (years) (mean (SD)) | 50.6 (17.3) | 43.1 (14.9) |
| Female (n (%)) | 11 (91.6) | 5 (62.5) |
| Polyarticular joint involvement (n (%)) | 12 (100) | 8 (100) |
| RF positivity (n (%)) | 7 (58) | 0 (0) |
| Entheseal involvement (n (%)) | 0 (0) | 7 (87.5) |
| Axial involvement (n (%)) | 0 (0) | 6 (75) |
| Knee joint involvement (n) | 17 | 10 |
| KJS duration (years) (mean (SD)) | 6.1 (4.8) | 6.0 (2.2) |
| ESR (mm/h) (mean (SD)) | 50.1 (25.1) | 41.5 (28.2) |
| C reactive protein (mg/dl) (mean (SD)) | 33.9 (21.9) | 22.6 (11.2) |
| Knee joint articular index (mean (SD)) | 3.9 (2.4) | 4.3 (2.7) |
| Mean DMARD use (n) | 3.3 | 3.4 |
| Mean IA knee joint injections (n) | 3.3 | 3.8 |
| Methotrexate use (n (%)) | 9 (52.9) | 6 (60) |
| Etanercept monotherapy (n (%)) | 6 (35.3) | 0 (0) |
| Etanercept combination therapy (n (%)) | 11 (64.7) | 10 (100) |
| Prednisone (n (%)) | 17 (100) | 10 (100) |